top of page

ASGCT 2026: Rgenta Therapeutics has been developing oral small molecules to regulate RNA - after starting with endogenous targets, they realized they could do the same for transgene expression

  • May 13
  • 1 min read

Co-Founder and CEO Simon Xi discusses the company's Rswitch platform, which was the basis of an ASGCT presentation showing that the company could modulate levels of Frataxin in a Friedreich’s Ataxia mouse model.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page